MedTrace Logo

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

NCT04109872 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-02-05

No results posted yet for this study

Summary

This is a multicentric, observational and retrospective study of the use of lenalidomide in patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL spanish program.

The lenalidomide effectiveness and tolerability data will be retrospectely collected until the 30 of April 2018.

Conditions

Interventions

DRUG

Lenalidomide

Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.

Sponsors & Collaborators

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • Carlos García Pérez · Hospital Universitario Virgen Macarena

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2020-06-15
Completion
2020-07-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04109872 on ClinicalTrials.gov